FDA Activity Round Up – July 2026

The FDA opened July with a stretch of activity that touched both ends of the pharmaceutical pipeline: a proposed regulatory update aimed at how manufacturing facilities register with the agency, and 3 new drug approvals spanning oncology and nephrology.1-4 Individually, each action addresses a narrow slice of drug development or oversight. Together, they point to a regulator increasingly attentive to how medicines are made, not only what they do.

What Would the Proposed Registration Rule Change for Manufacturers?

On July 10, 2026, the FDA issued a proposed rule intended to modernize how certain manufacturing facilities register their operations.1 The rule addresses 2 distinct problems, both rooted in registration requirements that have not kept pace with how drugs are produced.

The first concerns distributed manufacturing, an approach in which a company operates a network of manufacturing units, each capable of producing the same product, under a shared quality oversight structure often described as a hub-and-spoke model.1 Under current regulation, every unit in that network must register separately with the FDA, an administrative requirement that treats what is functionally a single manufacturing operation as though it were many. The proposed rule would allow distributed manufacturing establishments to register as 1 establishment, with units added, relocated, or removed through a streamlined update process. Companies would also be required to notify the FDA in advance of any unit relocation, closing what the agency described as a gap in its real-time oversight of where production is taking place.

“The FDA is proposing changes to our establishment registration regulations that would reflect how distributed manufacturing actually works—as 1 single establishment,” said Michael Davis, M.D., PhD, acting director of the FDA’s Center for Drug Evaluation and Research, in a press release.1 “The proposed changes would make it easier for innovative manufacturers to operate efficiently, and give the FDA a clearer, more accurate picture of how and where drugs are being made.”

The second element of the rule addresses foreign establishments that manufacture drug components, including APIs, exclusively for distribution to other foreign establishments.1 Under current practice, some of these facilities are not required to register with the FDA at all, which limits the agency's visibility into upstream segments of the supply chain. The proposed rule would clarify that these establishments must register and report on the drugs they produce, regardless of whether their output reaches the United States directly or only after passing through intermediate manufacturers abroad. Agency officials framed this as a matter of traceability, when an active ingredient in a medicine reaches a patient, the FDA should be able to identify where it originated, and the current registration gap makes that harder than it should be.

For quality and regulatory affairs teams, this change is more than just semantics.1 Registration and listing obligations shape internal recordkeeping systems, facility change-control procedures, and supply chain documentation. A streamlined pathway for distributed manufacturing could meaningfully reduce the administrative burden associated with adding capacity or relocating equivalent production units, which matters as more companies adopt modular or distributed production models to shorten supply chains and build in redundancy. At the same time, expanded foreign registration requirements mean that companies sourcing components internationally, even indirectly through intermediate suppliers, should expect closer scrutiny of where those materials originate and more paperwork tracing that origin. The rule is not yet final. The FDA will take public comment before deciding whether and how to proceed, but manufacturers running distributed operations or complex international sourcing arrangements have reason to track its progress and consider submitting comments while the rule is still open for input.

How Are Manufacturing and Formulation Choices Shaping Recent Approvals?

Three approvals issued in the same week point to a related trend: formulation and delivery decisions are increasingly central to how new therapies reach patients, and those decisions carry manufacturing implications of their own.2-4

On July 7, 2026, the FDA approved a new treatment for primary immunoglobulin A nephropathy, a serious kidney disease in which an abnormal antibody builds up in the kidneys and causes protein to leak from the blood into the urine, along with a loss of kidney function that can progress to kidney failure.2 The new therapy, atacicept-vymj, is the first FDA-approved medicine to target 2 proteins involved in the survival and maturation of certain immune cells, and it is self-administered by subcutaneous injection once weekly. It was granted accelerated approval on the basis of a 46% reduction in proteinuria compared with placebo after 9 months of treatment; whether it slows the underlying decline in kidney function over the long term has not yet been established, and the sponsor, Vera Therapeutics, must complete an ongoing confirmatory trial to maintain approval. The therapy also received priority review and Breakthrough Therapy designation, both of which are intended to speed development and review of treatments for serious conditions but do nothing to shorten the manufacturing runway a sponsor needs to prepare for launch. Accelerated approvals of this kind place particular pressure on manufacturing and process development teams, who must scale production to support both a confirmatory trial and a commercial launch at the same time, often before the manufacturing process has been fully optimized at commercial volumes.

The second approval, granted on July 9, 2026, was the subcutaneous formulation of isatuximab-irfc, an antibody previously available only as an intravenous infusion, across three separate combination regimens for adults with multiple myeloma who have received prior treatment or, in 1 regimen, who are newly diagnosed but not eligible for a stem cell transplant.3 The new formulation can be administered either through an on-body delivery device or manually, using a syringe and infusion set. Approval relied in part on a trial that randomized more than 500 patients to either the subcutaneous or intravenous version alongside standard combination therapy and found that roughly 7 in 10 patients responded to treatment in each arm, while the subcutaneous version produced higher steady-state drug exposure than the intravenous formulation. The therapy also carries orphan drug designation, reflecting its use in a relatively small patient population. Converting an intravenous biologic to a subcutaneous injectable is not simply a matter of concentrating the drug further; it typically requires new fill-finish processes, device-drug combination manufacturing and quality systems, and testing to confirm that patients or caregivers can use the delivery device safely and correctly. As more antibody therapies move in this direction to reduce infusion time and free up clinic capacity, manufacturers are increasingly expected to build or contract for this kind of device-integrated production capability well before a subcutaneous version reaches review.

The third approval, issued July 10, 2026, expanded the use of pembrolizumab, administered either in its standard intravenous form or as a subcutaneous coformulation with berahyaluronidase alfa-pmph, in combination with enfortumab vedotin-ejfv, for adults with muscle invasive bladder cancer before and after surgical removal of the bladder.4 The approval extends a regimen previously limited to patients who could not tolerate cisplatin-based chemotherapy to all patients who are candidates for surgery, based on a trial showing improved event-free and overall survival compared with standard chemotherapy given before surgery alone. The subcutaneous coformulation option again reflects the broader shift toward reducing time spent in infusion chairs, combination-product quality systems, and staff training for administration in the clinic.

Why Does International Regulatory Alignment Matter for Manufacturing Strategy?

The bladder cancer approval was also reviewed under Project Orbis, a framework that allows the FDA to review oncology applications concurrently with regulatory counterparts in other countries.4 The FDA completed its review 5 weeks ahead of its own goal date, though reviews at the other participating agencies remain ongoing.

Concurrent international review does not guarantee simultaneous approval across all participating countries, since each agency retains its own decision-making authority and timeline.1,4 But for manufacturers planning global launches, coordinated review reduces the likelihood of long gaps between approvals in different markets, which in turn affects how companies plan batch release schedules, labeling variations across regions, and the sequencing of distribution once approvals arrive. As more applications move through this kind of framework, manufacturing and supply chain teams may need to prepare for tighter, more overlapping launch windows across multiple jurisdictions rather than the staggered rollouts that have historically been more common in oncology.

This stretch of FDA activity reflects two parallel efforts: one to modernize the regulatory infrastructure that governs where and how drugs are made, and another to keep pace with how sponsors are changing what they make and how they deliver it.1-4 Both point toward a regulatory environment in which manufacturing strategy, including facility design, device integration, and international coordination, is treated as inseparable from the clinical case for a new medicine.

References

1. FDA proposes rule to modernize drug manufacturing registration. FDA. Press release. July 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-modernize-drug-manufacturing-registration
2. FDA approves new treatment to reduce Proteinuria in adults with Primary Immunoglobulin A Nephropathy. FDA. Press release. July 7, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy
3. FDA approves isatuximab-irfc subcutaneous injection for multiple myeloma indications. U.S. Food and Drug Administration. Press Release. July 10, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications
4. FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. U.S. Food and Drug Administration. Press Release. July 10, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin